DRY POWDER DRUG DELIVERY SYSTEM
A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
1 . An inhalation system, comprising:
a dry powder inhaler; and
a dry powder formulation comprising a plurality of powder particles of a diketopiperazine;
wherein the inhalation system is configured to deliver the diketopiperazine to the pulmonary circulation of a subject from a single inhalation.
2 . The inhalation system of claim 1 , further comprising a cartridge configured to adapt to said dry powder inhaler.
3 . The inhalation system of claim 1 , wherein the dry powder inhaler is a breath powered inhaler.
4 . The inhalation system of claim 3 , wherein the diketopiperazine is 3,6-bis-(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine.
5 . The inhalation system of claim 1 , wherein the dry powder formulation comprises an active ingredient.
6 . The inhalation system of claim 2 , wherein the cartridge containing a dry powder formulation is reconfigurable in the inhaler from a containment configuration to a dosing configuration.
7 . The inhalation system of claim 1 , wherein the diketopiperazine has a T max of less than 1 hour.
8 . The inhalation system of claim 5 , wherein the active ingredient is a protein, a peptide, a polypeptide or fragments thereof.
9 . The inhalation system of claim 5 , wherein the active ingredient is insulin.
10 . An inhalation system for pulmonary delivery of a drug, comprising:
a breath-powered dry powder inhaler, and
a dry powder formulation comprising a plurality of diketopiperazine particles;
wherein the inhalation system is operably configured to emit more than 90% of the dry powder formulation and the diketopiperazine particles that dissolve and are absorbed into the blood in less than 30 minutes yield a peak concentration of the diketopiperazine after a single inhalation of the dry powder formulation.